GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats

ACS Chemical Neuroscience

Volumn 4, Issue 5, 2013, Pages 808-816

  Mabrouk, Omar S ^a,b   Mela, Flora ^a,b,c   Calcagno, Mariangela ^a,b   Budri, Mirco ^a,b   Viaro, Riccardo ^a,d   Dekundy, Andrzej ^c   Parsons, Christopher G ^c   Auberson, Yves P ^e   Morari, Michele ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b National Institute of Neuroscience   (Italy)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

6 OHDA; GABA; microdialysis; NMDA receptor subunits; NVP AAM077; Ro 25 6981

Indexed keywords

4 AMINOBUTYRIC ACID; GLUN2A NMDA RECEPTOR; GLUN2B NMDA RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DYSKINESIA; HISTOLOGY; MALE; MICRODIALYSIS; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA PARS RETICULATA;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; GLUTAMIC ACID; LEVODOPA; MALE; MICRODIALYSIS; NEOSTRIATUM; OXIDOPAMINE; PHENOLS; PIPERIDINES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANTIA NIGRA;

EID: 84877800002     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400016d     Document Type: Article

References (57)

1. Chase, T. N. and Oh, J. D. (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism Trends Neurosci. 23, S86-91
2. Hallett, P. J. and Standaert, D. G. (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease Pharmacol. Ther. 102, 155-174
3. Sgambato-Faure, V. and Cenci, M. A. (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease Prog. Neurobiol. 96, 69-86
4. Meguro, H., Mori, H., Araki, K., Kushiya, E., Kutsuwada, T., Yamazaki, M., Kumanishi, T., Arakawa, M., Sakimura, K., and Mishina, M. (1992) Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs Nature 357, 70-74
5. Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., and Seeburg, P. H. (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes Science 256, 1217-1221
6. Dingledine, R., Borges, K., Bowie, D., and Traynelis, S. F. (1999) The glutamate receptor ion channels Pharmacol. Rev. 51, 7-61
7. Laurie, D. J. and Seeburg, P. H. (1994) Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition Eur. J. Pharmacol. 268, 335-345
8. Monaghan, D. T. and Larsen, H. (1997) NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology J. Pharmacol. Exp. Ther. 280, 614-620
9. Landwehrmeyer, G. B., Standaert, D. G., Testa, C. M., Penney, J. B., Jr., and Young, A. B. (1995) NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum J. Neurosci. 15, 5297-5307
10. Standaert, D. G., Friberg, I. K., Landwehrmeyer, G. B., Young, A. B., and Penney, J. B., Jr. (1999) Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat Brain Res. Mol. Brain Res. 64, 11-23
11. Mitchell, I. J., Hughes, N., Carroll, C. B., and Brotchie, J. M. (1995) Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset Behav. Pharmacol. 6, 492-507
12. Nash, J. E., Hill, M. P., and Brotchie, J. M. (1999) Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat Exp. Neurol. 155, 42-48
13. Nash, J. E., Fox, S. H., Henry, B., Hill, M. P., Peggs, D., McGuire, S., Maneuf, Y., Hille, C., Brotchie, J. M., and Crossman, A. R. (2000) Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease Exp. Neurol. 165, 136-142
14. Steece-Collier, K., Chambers, L. K., Jaw-Tsai, S. S., Menniti, F. S., and Greenamyre, J. T. (2000) Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors Exp. Neurol. 163, 239-243
15. Loschmann, P. A., De Groote, C., Smith, L., Wullner, U., Fischer, G., Kemp, J. A., Jenner, P., and Klockgether, T. (2004) Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease Exp. Neurol. 187, 86-93
16. Fantin, M., Auberson, Y. P., and Morari, M. (2008) Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism J. Neurochem. 106, 957-968
17. Fantin, M., Marti, M., Auberson, Y. P., and Morari, M. (2007) NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways J. Neurochem. 103, 2200-2211
18. Albin, R. L., Young, A. B., and Penney, J. B. (1989) The functional anatomy of basal ganglia disorders Trends Neurosci. 12, 366-375
19. Alexander, G. E. and Crutcher, M. D. (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing Trends Neurosci. 13, 266-271
20. Deniau, J. M. and Chevalier, G. (1985) Disinhibition as a basic process in the expression of striatal functions. II. The striato-nigral influence on thalamocortical cells of the ventromedial thalamic nucleus Brain Res. 334, 227-233
21. Cenci, M. A., Lee, C. S., and Bjorklund, A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10, 2694-2706
22. Dunah, A. W., Wang, Y., Yasuda, R. P., Kameyama, K., Huganir, R. L., Wolfe, B. B., and Standaert, D. G. (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease Mol. Pharmacol. 57, 342-352
23. Hallett, P. J., Dunah, A. W., Ravenscroft, P., Zhou, S., Bezard, E., Crossman, A. R., Brotchie, J. M., and Standaert, D. G. (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Neuropharmacology 48, 503-516
24. Gardoni, F., Picconi, B., Ghiglieri, V., Polli, F., Bagetta, V., Bernardi, G., Cattabeni, F., Di Luca, M., and Calabresi, P. (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia J. Neurosci. 26, 2914-2922
25. Rascol, O., Sabatini, U., Chollet, F., Celsis, P., Montastruc, J. L., Marc-Vergnes, J. P., and Rascol, A. (1992) Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine Arch. Neurol. 49, 144-148
26. Rascol, O., Sabatini, U., Brefel, C., Fabre, N., Rai, S., Senard, J. M., Celsis, P., Viallard, G., Montastruc, J. L., and Chollet, F. (1998) Cortical motor overactivation in parkinsonian patients with L-DOPA-induced peak-dose dyskinesia Brain 121 (Pt 3) 527-533
27. Jocoy, E. L., Andre, V. M., Cummings, D. M., Rao, S. P., Wu, N., Ramsey, A. J., Caron, M. G., Cepeda, C., and Levine, M. S. (2011) Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-d-aspartate currents by dopamine D1 receptor activation in striatum Front. Syst. Neurosci. 5, 28
28. Maranis, S., Stamatis, D., Tsironis, C., and Konitsiotis, S. (2012) Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia Eur. J. Pharmacol. 683, 71-77
29. Belujon, P., Lodge, D. J., and Grace, A. A. (2010) Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment Mov. Disord. 25, 1568-1576
30. Carta, A. R., Tronci, E., Pinna, A., and Morelli, M. (2005) Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment Eur. J. Neurosci. 21, 1196-1204
31. Picconi, B., Centonze, D., Rossi, S., Bernardi, G., and Calabresi, P. (2004) Therapeutic doses of L-DOPA reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism Brain 127, 1661-1669
32. Chaperon, F., Muller, W., Auberson, Y. P., Tricklebank, M. D., and Neijt, H. C. (2003) Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit Behav. Pharmacol. 14, 477-487
33. Lemay-Clermont, J., Robitaille, C., Auberson, Y. P., Bureau, G., and Cyr, M. (2011) Blockade of NMDA receptors 2A subunit in the dorsal striatum impairs the learning of a complex motor skill Behav. Neurosci. 125, 714-723
34. Wessell, R. H., Ahmed, S. M., Menniti, F. S., Dunbar, G. L., Chase, T. N., and Oh, J. D. (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rat Neuropharmacology 47, 184-194
35. Blanchet, P. J., Konitsiotis, S., Whittemore, E. R., Zhou, Z. L., Woodward, R. M., and Chase, T. N. (1999) Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys J. Pharmacol. Exp. Ther. 290, 1034-1040
36. Nutt, J. G., Gunzler, S. A., Kirchhoff, T., Hogarth, P., Weaver, J. L., Krams, M., Jamerson, B., Menniti, F. S., and Landen, J. W. (2008) Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism Mov. Disord. 23, 1860-1866
37. Rylander, D., Recchia, A., Mela, F., Dekundy, A., Danysz, W., and Cenci, M. A. (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling J. Pharmacol. Exp. Ther. 330, 227-235
38. Gardoni, F., Sgobio, C., Pendolino, V., Calabresi, P., Di Luca, M., and Picconi, B. (2012) Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias Neurobiol. Aging 33, 2138-2144
39. Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M., and Cenci, M. A. (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's diseas J. Neurochem. 101, 483-497
40. Bateup, H. S., Santini, E., Shen, W., Birnbaum, S., Valjent, E., Surmeier, D. J., Fisone, G., Nestler, E. J., and Greengard, P. (2010) Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors Proc. Natl. Acad. Sci. U.S.A. 107, 14845-14850
41. Mela, F., Marti, M., Bido, S., Cenci, M. A., and Morari, M. (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels Neurobiol. Dis. 45, 573-582
42. Marti, M., Sbrenna, S., Fuxe, K., Bianchi, C., Beani, L., and Morari, M. (2000) Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rat Eur. J. Neurosci. 12, 1848-1850
43. Marti, M., Mela, F., Fantin, M., Zucchini, S., Brown, J. M., Witta, J., Di Benedetto, M., Buzas, B., Reinscheid, R. K., Salvadori, S., Guerrini, R., Romualdi, P., Candeletti, S., Simonato, M., Cox, B. M., and Morari, M. (2005) Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease J. Neurosci. 25, 9591-9601
44. Paxinos, G. and Watson, C. (1986) The rat brain in stereotaxic coordinates, 2 nd ed., Academic Press, Sydney; Orlando.
45. Marti, M., Mela, F., Bianchi, C., Beani, L., and Morari, M. (2002) Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors J. Neurochem. 83, 635-644
46. Marti, M., Trapella, C., Viaro, R., and Morari, M. (2007) The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway J. Neurosci. 27, 1297-1307
47. Cenci, M. A. and Lundblad, M. (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice, Current Protocols in Neuroscience, Chapter 9, Unit 9 25. DOI: 10.1002/0471142301.ns0925s41.
48. Bido, S., Marti, M., and Morari, M. (2011) Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels J. Neurochem. 118, 1043-1055
49. Marti, M., Rodi, D., Li, Q., Guerrini, R., Fasano, S., Morella, I., Tozzi, A., Brambilla, R., Calabresi, P., Simonato, M., Bezard, E., and Morari, M. (2012) Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias J. Neurosci. 32, 16106-16119
50. Auberson, Y. P., Allgeier, H., Bischoff, S., Lingenhoehl, K., Moretti, R., and Schmutz, M. (2002) 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition Bioorg. Med. Chem. Lett. 12, 1099-1102
51. Liu, L., Wong, T. P., Pozza, M. F., Lingenhoehl, K., Wang, Y., Sheng, M., Auberson, Y. P., and Wang, Y. T. (2004) Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity Science 304, 1021-1024
52. Feng, B., Tse, H. W., Skifter, D. A., Morley, R., Jane, D. E., and Monaghan, D. T. (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid Br. J. Pharmacol. 141, 508-516
53. Frizelle, P. A., Chen, P. E., and Wyllie, D. J. (2006) Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4- tetrahydroquinoxalin-5 -yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission Mol. Pharmacol. 70, 1022-1032
54. Neyton, J. and Paoletti, P. (2006) Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach J. Neurosci. 26, 1331-1333
55. Berberich, S., Punnakkal, P., Jensen, V., Pawlak, V., Seeburg, P. H., Hvalby, O., and Kohr, G. (2005) Lack of NMDA receptor subtype selectivity for hippocampal long-term potentiation J. Neurosci. 25, 6907-6910
56. Mutel, V., Buchy, D., Klingelschmidt, A., Messer, J., Bleuel, Z., Kemp, J. A., and Richards, J. G. (1998) In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits J. Neurochem. 70, 2147-2155
57. Fischer, G., Mutel, V., Trube, G., Malherbe, P., Kew, J. N., Mohacsi, E., Heitz, M. P., and Kemp, J. A. (1997) Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro J. Pharmacol. Exp. Ther. 283, 1285-1292